Literature DB >> 12750165

Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions.

Nathalie Rufer1, Alfred Zippelius, Pascal Batard, Mikael J Pittet, Isabel Kurth, Patricia Corthesy, Jean-Charles Cerottini, Serge Leyvraz, Eddy Roosnek, Markus Nabholz, Pedro Romero.   

Abstract

After antigenic challenge, naive T lymphocytes enter a program of proliferation and differentiation during the course of which they acquire effector functions and may ultimately become memory cells. In humans, the pathways of effector and memory T-cell differentiation remain poorly defined. Here we describe the properties of 2 CD8+ T-lymphocyte subsets, RA+CCR7-27+28+ and RA+CCR7-27+28-, in human peripheral blood. These cells display phenotypic and functional features that are intermediate between naive and effector T cells. Like naive T lymphocytes, both subsets show relatively long telomeres. However, unlike the naive population, these T cells exhibit reduced levels of T-cell receptor excision circles (TRECs), indicating they have undergone additional rounds of in vivo cell division. Furthermore, we show that they also share effector-type properties. At equivalent in vivo replicative history, the 2 subsets express high levels of Fas/CD95 and CD11a, as well as increasing levels of effector mediators such as granzyme B, perforin, interferon gamma, and tumor necrosis factor alpha. Both display partial ex vivo cytolytic activity and can be found among cytomegalovirus-specific cytolytic T cells. Taken together, our data point to the presence of T cells with intermediate effector-like functions and suggest that these subsets consist of T lymphocytes that are evolving toward a more differentiated effector or effector-memory stage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750165     DOI: 10.1182/blood-2003-02-0420

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

Review 1.  The transcriptional control of the perforin locus.

Authors:  Matthew E Pipkin; Anjana Rao; Mathias G Lichtenheld
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals.

Authors:  Elizabeth Sinclair; Douglas Black; C Lorrie Epling; Alexander Carvidi; Steven Z Josefowicz; Barry M Bredt; Mark A Jacobson
Journal:  Viral Immunol       Date:  2004       Impact factor: 2.257

3.  Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.

Authors:  Lisa Marie Serrano; Timothy Pfeiffer; Simon Olivares; Tontanai Numbenjapon; Jennifer Bennitt; Daniel Kim; David Smith; George McNamara; Zaid Al-Kadhimi; Joseph Rosenthal; Stephen J Forman; Michael C Jensen; Laurence J N Cooper
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

4.  Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.

Authors:  Martine E D Chamuleau; Theresia M Westers; Linda van Dreunen; Judith Groenland; Adri Zevenbergen; Corien M Eeltink; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

5.  Cortisol and epinephrine control opposing circadian rhythms in T cell subsets.

Authors:  Stoyan Dimitrov; Christian Benedict; Dennis Heutling; Jürgen Westermann; Jan Born; Tanja Lange
Journal:  Blood       Date:  2009-03-17       Impact factor: 22.113

6.  Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers.

Authors:  Camille Lécuroux; Asier Sáez-Cirión; Isabelle Girault; Pierre Versmisse; Faroudy Boufassa; Véronique Avettand-Fenoël; Christine Rouzioux; Laurence Meyer; Gianfranco Pancino; Olivier Lambotte; Martine Sinet; Alain Venet
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

7.  HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo.

Authors:  Aude G Chapuis; Corey Casper; Steve Kuntz; Jia Zhu; Annelie Tjernlund; Kurt Diem; Cameron J Turtle; Melinda L Cigal; Roxanne Velez; Stanley Riddell; Lawrence Corey; Philip D Greenberg
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

8.  IL-12 selectively programs effector pathways that are stably expressed in human CD8+ effector memory T cells in vivo.

Authors:  Fatema Z Chowdhury; Hilario J Ramos; Laurie S Davis; James Forman; J David Farrar
Journal:  Blood       Date:  2011-08-10       Impact factor: 22.113

9.  Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?

Authors:  Arne N Akbar; Sian M Henson
Journal:  Nat Rev Immunol       Date:  2011-04       Impact factor: 53.106

Review 10.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.